表紙
市場調査レポート

転移性ぶどう膜黒色腫:パイプライン製品の分析

Metastatic Uveal Melanoma - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 305183
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
転移性ぶどう膜黒色腫:パイプライン製品の分析 Metastatic Uveal Melanoma - Pipeline Review, H2 2014
出版日: 2014年10月25日 ページ情報: 英文 58 Pages
概要

転移性ぶどう膜黒色腫とは、眼球(ぶどう膜)から人体の他の部位へと転移していくがんを指します。肝臓への転移が最も多く、また肺・骨・皮膚直下(皮下)への転移も多く見られます。主な症状には黄疸や皮膚の痒み・発疹、肝臓内部の酵素の異常増加、腹痛、食欲不振、吐き気・嘔吐などが挙げられます。主な治療法には、外科手術や化学療法、放射線治療などがあります。

当レポートでは、世界各国での転移性ぶどう膜黒色腫治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

転移性ぶどう膜黒色腫の概要

治療薬の開発

  • 転移性ぶどう膜黒色腫向けパイプライン製品:概要
  • 転移性ぶどう膜黒色腫向けパイプライン製品:比較分析

各企業で開発中の転移性ぶどう膜黒色腫治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品

転移性ぶどう膜黒色腫治療薬:開発中の製品の一覧(企業別)

転移性ぶどう膜黒色腫治療薬の開発に従事している企業

  • AstraZeneca PLC
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.

転移性ぶどう膜黒色腫:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 硫酸セルメチニブ
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • リンゴ酸スニチニブ
  • 硫酸ビンクリスチン・リポソーム
  • LY-2801653
  • 酢酸ソトラスタウリン
  • MEK-162

転移性ぶどう膜黒色腫治療薬:パイプライン製品の最新動向

転移性ぶどう膜黒色腫治療薬:開発が休止状態の製品

転移性ぶどう膜黒色腫の関連製品の開発マイルストーン

  • 注目すべき最新動向・プレスリリース(全2件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5642IDB

Summary

Global Markets Direct's, 'Metastatic Uveal Melanoma - Pipeline Review, H2 2014', provides an overview of the Metastatic Uveal Melanoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Uveal Melanoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Uveal Melanoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Uveal Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Uveal Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Uveal Melanoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Uveal Melanoma Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Uveal Melanoma - Overview
    • Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis
  • Metastatic Uveal Melanoma - Therapeutics under Development by Companies
  • Metastatic Uveal Melanoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Metastatic Uveal Melanoma - Products under Development by Companies
  • Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development
    • AstraZeneca PLC
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Novartis AG
    • Spectrum Pharmaceuticals, Inc.
  • Metastatic Uveal Melanoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • selumetinib sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vincristine sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trametinib dimethyl sulfoxide + uprosertib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LY-2801653 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sotrastaurin acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • binimetinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • emibetuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Metastatic Uveal Melanoma - Recent Pipeline Updates
  • Metastatic Uveal Melanoma - Dormant Projects
  • Metastatic Uveal Melanoma - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2013: AstraZeneca's New Therapy Selumetinib Improves Progression-Free Survival And Shrink Tumors In Metastatic Uveal Melanoma, Researchers Report
      • May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Uveal Melanoma, H2 2014
  • Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Metastatic Uveal Melanoma - Pipeline by AstraZeneca PLC, H2 2014
  • Metastatic Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2014
  • Metastatic Uveal Melanoma - Pipeline by GlaxoSmithKline plc, H2 2014
  • Metastatic Uveal Melanoma - Pipeline by Novartis AG, H2 2014
  • Metastatic Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Metastatic Uveal Melanoma Therapeutics - Recent Pipeline Updates, H2 2014
  • Metastatic Uveal Melanoma - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Metastatic Uveal Melanoma, H2 2014
  • Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top